Core Viewpoint - China National Airlines announced a plan to sell approximately 1.61% of its stake in Cathay Pacific through a block trade, with an expected total transaction value of HKD 1.32 billion, aiming to realize a pre-tax profit of approximately RMB 182 million from the sale [1][4]. Group 1: Transaction Details - The sale involves 108,080,000 shares at a price of HKD 12.22 per share [1]. - The transaction is expected to be completed before a special shareholders' meeting [4]. - Following the sale, China National Airlines' stake in Cathay Pacific will decrease from approximately 28.72% to 27.11% [8]. Group 2: Stakeholder Changes - After the completion of the sale and a share buyback, Swire Group's ownership in Cathay Pacific will increase from about 43.09% to approximately 47.65% [4]. - Qatar Airways will maintain its stake at 9.57% post-transaction [7]. Group 3: Company Performance - Cathay Pacific's stock price has risen over 40% in 2025, closing at HKD 13.09 per share on January 5, 2026 [8]. - The airline expects strong performance in the second half of the year, driven by increased capacity and resilient cargo demand, along with a non-recurring income of approximately HKD 900 million from a supplier settlement [9]. - UBS has raised Cathay Pacific's target price by 9% from HKD 14 to HKD 15.3, maintaining a "buy" rating, citing the airline as one of the most promising in the Asia-Pacific aviation sector [9].

佑驾创新(02431)发布公告，董事会已决议，根据于2025年5月23日举行的股东周年大会上授予公司董事 及经公司股东批准的一般授权，不时在香港联合交易所有限公司的公开市场上购回公司的H股股份，总 金额不超过2亿港元。股份购回授权的期限为自股东周年大会审议通过之日起，至以下较早日期届满： (i)于公司下届股东周年大会结束后，届时该项授权将告失效，除非该会议通过特别决议案无条件或有条 件地予以延续;或(ii)公司任何股东大会通过特别决议案撤销或更改本议案的授权之日。 ...

证券日报网讯 1月6日，九丰能源在互动平台回答投资者提问时表示，公司第五次股份回购计划正在按 照计划有序推进中，截至2025年12月31日，公司以集中竞价交易方式累计回购股份768.98万股，占公司 总股本的1.09%，已支付的资金总额为人民币23374.54万元（不含交易费用）。公司将持续关注股价变 动，若有修改回购股份价格上限等情形，公司将按照相关法律法规的要求履行信息披露义务。 （文章来源：证券日报） ...

广汇物流公告称，公司以集中竞价方式回购股份用于减少注册资本。预计回购2-4亿元，期限为2024年7 月31日至2026年4月30日。截至2025年12月31日，累计回购1477.04万股，占总股本1.24%，支付总金额 8498.54万元，回购价为4.62-10.96元/股，符合相关规定及回购方案。公司将依规在期限内择机回购并及 时披露。 ...

Core Viewpoint - The company has successfully completed its share repurchase plan, having repurchased a total of 4,150,049 shares, which represents 2.14% of its total share capital, with the total amount spent nearing the upper limit of the repurchase fund [1] Summary by Sections Share Repurchase Details - As of December 31, 2025, the company repurchased 1,306,500 shares, accounting for 0.67% of the total share capital, with a total transaction amount of 30,025,237 RMB [1] - By January 5, 2026, the total shares repurchased increased to 2,593,049, representing 1.34% of the total share capital, with a total transaction amount of 61,132,076.92 RMB [1] - As of January 6, 2026, the cumulative repurchase reached 4,150,049 shares, or 2.14% of the total share capital, with a total transaction amount of 99,878,350.92 RMB [1] Price Range - The highest transaction price during the repurchase was 25.18 RMB per share, while the lowest was 22.27 RMB per share [1]

Core Viewpoint - The company, 理工能科 (002322.SZ), has completed its share repurchase program, acquiring a total of 13,620,000 shares, which represents 3.59% of its total share capital [1] Summary by Relevant Sections Share Repurchase Details - The company utilized its own funds to repurchase shares through a dedicated securities account via centralized bidding [1] - The repurchase occurred between February 10, 2025, and January 5, 2026 [1] - The total amount paid for the repurchased shares was 178,619,427 yuan, excluding transaction fees [1] Price Range and Volume - The highest transaction price for the repurchased shares was 14.42 yuan per share, while the lowest was 11.72 yuan per share [1] - The total number of shares repurchased is 13,620,000, out of a total share capital of 379,147,970 shares [1] Compliance and Financial Limits - The total funds used for the repurchase exceeded the lower limit of 90 million yuan set in the repurchase plan but did not exceed the upper limit of 180 million yuan [1] - The repurchase was conducted in accordance with the company's established repurchase plan, report, and relevant laws and regulations [1]

Core Viewpoint - Songcheng Performance announced a share buyback plan, executing the repurchase of 1,222,000 shares, which represents 0.05% of the company's total shares outstanding [1] Summary by Relevant Sections - **Share Buyback Details** - The company repurchased shares through a dedicated securities account via centralized bidding [1] - The highest transaction price was 8.20 yuan per share, while the lowest was 8.17 yuan per share [1] - The total transaction amount reached 10,001,850 yuan, excluding transaction fees [1] - **Compliance and Regulations** - The buyback aligns with the company's established share repurchase plan and complies with relevant laws and regulations [1]

Group 1 - The company approved a share repurchase plan using its own funds to buy back A-shares through the Shanghai Stock Exchange, with a maximum repurchase price of RMB 315 per share and a total repurchase amount between RMB 200 million and RMB 250 million [2] - The repurchase period is set for 10 months from the date of board approval [2] - The company will use the repurchased shares for employee stock ownership plans or equity incentives [2] Group 2 - As of December 31, 2025, the company has repurchased a total of 402,976 shares, accounting for 0.29% of the total share capital of 141,030,049 shares, with a total expenditure of RMB 99.923 million [3] - The highest purchase price was RMB 256 per share, while the lowest was RMB 235 per share [3] - The repurchase progress aligns with the established repurchase plan [4] Group 3 - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations in a timely manner [5]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 烟台东诚药业集团股份有限公司（以下简称"公司"）于2025年12月31日召开第六届董事会第十七次会 议，审议通过了《关于以集中竞价方式回购股份方案的议案》，具体内容详见公司于2026年1月5日在指 定媒体《中国证券报》、《证券时报》、《上海证券报》、《证券日报》及巨潮资讯网 （www.cninfo.com.cn）披露的相关公告。 根据《深圳证券交易所上市公司自律监管指引第9号一一回购股份》等相关规定，现将公司董事会公告 回购股份决议前一个交易日（2025年12月31日）登记在册的前十名股东和前十名无限售条件股东的名 称、持股数量、持股比例情况公告如下： ■ 注：以上股东的持股数量为合并普通账户和融资融券信用账户后总的持股数量。 三、报备文件 中国证券登记结算有限责任公司深圳分公司股份查询相关文件 特此公告 烟台东诚药业集团股份有限公司董事会 2026年1月6日 一、前十名股东持股情况 ■ 注：以上股东的持股数量为合并普通账户和融资融券信用账户后总的持股数量。 二、 ...

具体内容详见公司于2025年12月16日、2025年12月23日在上海证券交易所网站（www.sse.com.cn）披露 的《荣昌生物关于以集中竞价交易方式回购股份的预案》（公告编号：2025-055）、《荣昌生物制药 （烟台）股份有限公司关于以集中竞价交易方式回购股份的回购报告书》（公告编号：2025-058）。 二、回购股份的进展情况 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、回购股份的基本情况 荣昌生物制药（烟台）股份有限公司（以下简称"公司"）于2025年12月15日召开第二届董事会第三十二 次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》。同意公司使用自有资金 和/或自筹资金以集中竞价交易方式回购公司已发行的部分人民币普通股（A股）股票，拟回购资金总额 不低于人民币2,000万元（含）且不超过人民币4,000万元（含），回购的股份将在未来合适的时机用于 员工持股计划或股权激励，回购价格不超过人民币95元/股（含），回购股 ...